Richard A. Scolyer
Impact in
- Oncology top 0.01%
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 519
- Cutaneous Melanoma Detection and Management 365
- Cancer Immunotherapy and Biomarkers 130
- CAR-T cell therapy research 82
-
- Melanoma and MAPK Pathways 178
- Co-authors
- John F. Thompson (251 shared papers)Georgina V. Long (251 shared papers)Richard Kefford (69 shared papers)Alexander M. Menzies (141 shared papers)James S. Wilmott (132 shared papers)Rajmohan Murali (59 shared papers)Lauren E. Haydu (49 shared papers)Stanley W. McCarthy (57 shared papers)
- Journals
- Journal of Clinical Oncology (67 papers)Pathology (59 papers)Annals of Surgical Oncology (52 papers)Annals of Oncology (27 papers)Modern Pathology (25 papers)
- Partner nations
- AustraliaUnited StatesNetherlands
In The Last Decade
Richard A. Scolyer
693 papers receiving 32.1k citations
Richard A. Scolyer's Hit Papers
Peers
Comparison fields: 5 of 166
- Oncology 19.9k
- Immunology 5.6k
- Cancer Research 3.5k
- Dermatology 2.1k
- Molecular Biology 11.9k
Countries citing papers authored by Richard A. Scolyer
This map shows the geographic impact of Richard A. Scolyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard A. Scolyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard A. Scolyer more than expected).
Fields of papers citing papers by Richard A. Scolyer
This network shows the impact of papers produced by Richard A. Scolyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard A. Scolyer. The network helps show where Richard A. Scolyer may publish in the future.
Co-authors
The 25 scholars most cited alongside Richard A. Scolyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 725 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual Hit paper breakdown → | 2017 | 1510 |
| 2 | Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma Hit paper breakdown → | 2011 | 844 |
| 3 | Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study Hit paper breakdown → | 2018 | 687 |
| 4 | Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma Hit paper breakdown → | 2012 | 630 |
| 5 | Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma Hit paper breakdown → | 2011 | 525 |
| 6 | Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance Hit paper breakdown → | 2012 | 487 |
| 7 | Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade Hit paper breakdown → | 2019 | 446 |
| 8 | Resistance to PD1/PDL1 checkpoint inhibition Hit paper breakdown → | 2016 | 440 |
| 9 | A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention Hit paper breakdown → | 2015 | 428 |
| 10 | Cutaneous melanoma Hit paper breakdown → | 2023 | 403 |
| 11 | 2014 | 396 | |
| 12 | 2012 | 352 | |
| 13 | 2014 | 340 | |
| 14 | 2018 | 332 | |
| 15 | The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway Hit paper breakdown → | 2020 | 332 |
| 16 | 2017 | 328 | |
| 17 | 2003 | 310 | |
| 18 | WHO classification of skin tumours | 2018 | 284 |
| 19 | 2018 | 279 | |
| 20 | 2015 | 267 |
About Richard A. Scolyer
Richard A. Scolyer is a scholar working on Oncology, Molecular Biology, Immunology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 725 papers that have together received 32.7k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (365 papers), Melanoma and MAPK Pathways (178 papers), Cancer Immunotherapy and Biomarkers (130 papers), Immunotherapy and Immune Responses (85 papers), CAR-T cell therapy research (82 papers), Cancer Genomics and Diagnostics (62 papers), Nonmelanoma Skin Cancer Studies (35 papers) and Sarcoma Diagnosis and Treatment (18 papers). The work is most often cited by research in Oncology (19.9k citations), Immunology (5.6k citations), Cancer Research (3.5k citations), Dermatology (2.1k citations) and Molecular Biology (11.9k citations). Richard A. Scolyer has collaborated with scholars based in Australia, United States and Netherlands. Frequent co-authors include John F. Thompson, Georgina V. Long, Richard Kefford, Alexander M. Menzies, James S. Wilmott, Rajmohan Murali, Lauren E. Haydu, Stanley W. McCarthy, Robyn P.M. Saw and Matteo S. Carlino. Their work appears in journals such as Journal of Clinical Oncology, Pathology, Annals of Surgical Oncology, Annals of Oncology and Modern Pathology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.